dc.contributor.author | Orkin, C | |
dc.contributor.author | Elion, R | |
dc.contributor.author | Thompson, M | |
dc.contributor.author | Rockstroh, JK | |
dc.contributor.author | Alvarez Bognar, F | |
dc.contributor.author | Xu, ZJ | |
dc.contributor.author | Hwang, C | |
dc.contributor.author | Sklar, P | |
dc.contributor.author | Martin, EA | |
dc.date.accessioned | 2021-03-26T14:47:19Z | |
dc.date.available | 2021-03-26T14:47:19Z | |
dc.date.issued | 2021-01-01 | |
dc.identifier.citation | Orkin, Chloea; Elion, Richardb; Thompson, Melaniec; Rockstroh, Juergen K.d; Alvarez Bognar, Fernandoe; Xu, Zhi J.f; Hwang, Careyg; Sklar, Peterg; Martin, Elizabeth A.g Changes in weight and BMI with first-line doravirine-based therapy, AIDS: January 1, 2021 - Volume 35 - Issue 1 - p 91-99 doi: 10.1097/QAD.0000000000002725 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/70901 | |
dc.description.abstract | OBJECTIVE: To evaluate changes in weight and BMI in adults with HIV-1 at 1 and 2 years after starting an antiretroviral regimen that included doravirine, ritonavir-boosted darunavir, or efavirenz. DESIGN: Post-hoc analysis of pooled data from three randomized controlled trials. METHODS: We evaluated weight change from baseline, weight gain at least 10%, and increase in BMI after 48 and 96 weeks of treatment with doravirine, ritonavir-boosted darunavir, or efavirenz-based regimens. Risk factors for weight gain and metabolic outcomes associated with weight gain were also examined. RESULTS: Mean (and median) weight changes were similar for doravirine [1.7 (1.0) kg] and ritonavir-boosted darunavir [1.4 (0.6) kg] and were lower for efavirenz [0.6 (0.0) kg] at week 48 but were similar across all treatment groups at week 96 [2.4 (1.5), 1.8 (0.7), and 1.6 (1.0) kg, respectively]. No significant differences between treatment groups were found in the proportion of participants with at least 10% weight gain or the proportion with BMI class increase at either time point. Low CD4 T-cell count and high HIV-1 RNA at baseline were associated with at least 10% weight gain and BMI class increase at both timepoints, but treatment group, age, sex, and race were not. CONCLUSION: Weight gains over 96 weeks were low in all treatment groups and were similar to the average yearly change in adults without HIV-1. Significant weight gain and BMI class increase were similar across the treatment groups and were predicted by low baseline CD4 T-cell count and high baseline HIV-1 RNA. | en_US |
dc.format.extent | 91 - 99 | |
dc.language | eng | |
dc.relation.ispartof | AIDS | |
dc.rights | Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.title | Changes in weight and BMI with first-line doravirine-based therapy. | en_US |
dc.type | Article | en_US |
dc.rights.holder | (c) 2020 The Author(s). Published by Wolters Kluwer Health, Inc | |
dc.identifier.doi | 10.1097/QAD.0000000000002725 | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33048879 | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 35 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |